Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 1, 2013, Pages 168-176

  Crowther, Grace S ^a   Baines, Simon D ^a   Todhunter, Sharie L ^a   Freeman, Jane ^b   Chilton, Caroline H ^a   Wilcox, Mark H ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Chemostat; Gut microflora; Ribotype

Indexed keywords

CEFTRIAXONE; CYTOTOXIN; NVB 302; VANCOMYCIN;

ARTICLE; BACTEROIDES FRAGILIS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; GERMINATION; IN VITRO STUDY; INTESTINE FLORA; NONHUMAN;

AGED; ANTI-BACTERIAL AGENTS; BACTERIOCINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG EVALUATION, PRECLINICAL; FECES; GASTROINTESTINAL TRACT; HUMANS; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN;

EID: 84871182628     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks359     Document Type: Article

References (35)

1. George WL, Rolfe RD, Finegold SM. Clostridium difficile and its cytotoxin in feces of patients with antimicrobial agent-associated diarrhea and miscellaneous conditions. J Clin Microbiol 1982; 15: 1049-53.
2. George WL, Rolfe RD, Harding GK et al. Clostridium difficile and cytotoxin in feces of patients with antimicrobial agent-associated pseudo-membranous colitis. Infection 1982; 10: 205-8.
3. Larson HE, Price AB, Honour P et al. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet 1978; i: 1063-6.
4. Wiegand PN, Nathwani D, Wilcox MH et al. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 2012; 81: 1-14.
5. Teasley DG, Gerding DN, Olson MM et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983; ii: 1043-6.
6. Zar FA, Bakkanagari SR, Moorthi KM et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-7.
7. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am J Health Syst Pharm 1998; 55: 1407-11.
8. Fekety R, Silva J, Kauffman C et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989; 86: 15-9.
9. Pepin J, Alary ME, Valiquette L et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40: 1591-7.
10. Musher DM, Aslam S, Logan N et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40: 1586-90.
11. Brazier JS, Fawley W, Freeman J et al. Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother 2001; 48: 741-2.
12. Baines SD, O'Connor R, Freeman J et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62: 1046-52.
13. HPA. Clostridium difficile Ribotyping Network (CDRN) for England and Northern Ireland 2010/11 Annual Report. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1296681523205 (12 July 2012, date last accessed).
14. Wadman SN, Citron DM, Choi S et al. NVB302: in vitro activity against Clostridium difficile and other intestinal strains of anaerobic bacteria. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract F1-1518, p. 101. American Society for Microbiology, Washington, DC, USA.
15. Baines SD, Huscroft GS, Todhunter SL et al. NVB302: in vitro activity against Clostridium difficile. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract F-1519, p. 101. American Society for Microbiology, Washington, DC, USA.
16. Baines SD, Freeman J, Wilcox MH. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. J Antimicrob Chemother 2005; 55: 974-82.
17. Wilcox MH, Baines SD, Noel AR et al. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model. J Antimicrob Chemother 2011; 66: 1537-46.
18. Wilcox MH, Freeman J, O'Neill FJ. Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut. J Antimicrob Chemother 2003; 52: 96-102.
19. Freeman J, Baines SD, Saxton K et al. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother 2007; 60: 83-91.
20. Baines SD, O'Connor R, Saxton K et al. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J Antimicrob Chemother 2008; 62: 1078-85.
21. Baines SD, O'Connor R, Saxton K et al. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 2009; 63: 520-5.
22. Baines SD, O'Connor R, Huscroft G et al. Mecillinam: a low-risk antimicrobial agent for induction of Clostridium difficile infection in an in vitro human gut model. J Antimicrob Chemother 2009; 63: 838-9.
23. Macfarlane GT, Macfarlane S, Gibson GR. Validation of a three-stage compound continuous culture system for investigating the effect of retention time on the ecology and metabolism of bacteria in the human colon. Microb Ecol 1998; 35: 180-7.
24. Freeman J, Baines SD, Jabes D et al. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother 2005; 56: 717-25.
25. Pletz MW, Rau M, Bulitta J et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Chemother 2004; 48: 3765-72.
26. Barbut F, Richard A, Hamadi K et al. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000; 38: 2386-8.
27. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-31.
28. Cornely OA, Crook DW, Esposito R et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12: 281-9.
29. de Lalla F, Privitera G, Ortisi G et al. Third generation cephalosporins as a risk factor for Clostridium difficile-associated disease: a four-year survey in a general hospital. J Antimicrob Chemother 1989; 23: 623-31.
30. Kidwai M, Sapra P, Bhushan KR. Synthetic strategies and medicinal properties of b-lactams. Curr Med Chem 1999; 6: 195-215.
31. Moeck G, Arhin FF et al. In vitro activity profile of oritavancin against a broad spectrum of aerobic and anaerobic bacterial pathogens. In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007. Abstract E-1612, p. 204. American Society for Microbiology, Washington, DC, USA.
32. Louie TJ, Emery J, Krulicki W et al. OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 2009; 53: 261-3.
33. Levett PN. Time-dependent killing of Clostridium difficile by metronidazole and vancomycin. J Antimicrob Chemother 1991; 27: 55-62.
34. Walters BA, Roberts R, Stafford R et al. Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy. Gut 1983; 24: 206-12.
35. Wadman SN, Appleyard AN, Candiani G et al. NVB302: gastro-intestinal stability and in vivo activity in the hamster cecitis model for Clostridium difficile infection. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract F1-1520, p. 101. American Society for Microbiology, Washington, DC, USA.